CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Coherus Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.96−0.03 (-3.16%)
Close on Oct 19, 2026
- Market cap
- $148.42M
- P/E (TTM)
- 0.7
- Dividend yield
- –
Coherus Oncology, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LOQTORZI | $40.84M | $19.13M | $554.00K | – | – | – | – | – | – | – | 96.8% | +113.5% |
| Other revenue | $1.34M | $7.26M | $664.00K | $282.00K | $42.00K | – | – | – | – | – | 3.2% | -81.6% |
| Total net product revenue | – | $259.70M | $256.58M | $210.76M | $326.51M | $475.82M | $356.10M | $0 | $0 | – | – | – |
| Collaboration and License Revenue | – | – | – | – | – | – | $0 | $0 | $1.56M | – | – | – |
| UDENYCA | – | $205.95M | $127.06M | $203.81M | $326.51M | $475.82M | – | – | – | – | – | – |
| CIMERLI | – | $27.08M | $125.39M | $6.95M | – | – | – | – | – | – | – | – |
| YUSIMRY | – | $7.54M | $3.57M | – | – | – | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | – | – | – | – | – | $356.07M | $0 | $0 | $188.29M | – | – |
| Rest of the world | – | – | – | – | – | – | $0 | $0 | $1.56M | $1.81M | – | – |
From the segment and revenue-disaggregation notes of Coherus Oncology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.